Guillain-Barré syndrome: clinical features, treatment choices and outcomes in an Australian cohort.
Guillain-Barré syndrome (GBS) causes acute neuromuscular weakness. Severe cases are life-threatening and many are left disabled. Intravenous immunoglobulin (IVIg) or plasma exchange (PE), with supportive care, are the mainstays of treatment. Multiple factors influence treatment choice. Clinico-epidemiological features of GBS in Australia have not been reviewed in 30 years and few studies have assessed contemporary treatment choices. We aimed to investigate the clinico-epidemiological features, choice of treatment, clinical course and outcomes of GBS patients in an Australian tertiary metropolitan hospital. A retrospective observational study was performed of GBS presentations to a tertiary hospital in Sydney, Australia over five years. Clinico-epidemiological features, treatment choices, clinical course and outcomes were assessed. We reviewed 46 GBS patients (54% male), average age 55 years. Antecedent infection was identified in 61%. 28% had preceding immunogenic events or conditions. Acute inflammatory demyelinating polyradiculoneuropathy was most common (78%). CSF albumino-cytologic dissociation was present in 43%. Electrodiagnostic testing most frequently demonstrated demyelination (64%). 98% received immunotherapy, mostly IVIg (93%). 22% received further treatment due to treatment-related fluctuations or lack of improvement. 13% required ICU admission and 46% needed rehabilitation. There were no deaths or need for mechanical ventilation. 71% of the follow up cohort had residual disability at six months but this was generally mild. The clinico-epidemiological features are consistent with previous cohorts. Our experience in a large Australian tertiary centre demonstrates a clear preference for IVIg over PE. This article is protected by copyright. All rights reserved.